Fostair® 100/6 (BDP/FF) pressurized metered dose inhaler (pMDI) delivered in an extrafine formulation is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the clinical effectiveness of BDP/FF against other licensed ICS/LABA combination inhalers: Seretide® Accuhaler® (FP/SAL) and Symbicort® Turbohaler® (BUD/FF).
A matched historical cohort study was conducted using records of patients with diagnostic codes for COPD from the Optimum Patient Care Research Database (OPCRD). Patients who received BDP/FF as their first ICS/LABA were matched 1:1 with patients who received FP/SAL or BUD/FF, resulting in two matched comparisons. Additional analysis was conducted on patients who never had diagnostic codes for asthma. Non-inferiority in terms of the proportion of patients with moderate/severe COPD exacerbation on the different inhalers in the following year was assessed. Non-inferiority was achieved if the higher confidence interval was ≤1.2.
This study included 537 and 540 patient pairs in the BDP/FF vs FP/SAL cohort and the BDP/FF vs BUD/FF cohort respectively. The proportion of patients with COPD exacerbations in the BDP/FF group was not significantly different to both FP/SAL (68.7% vs 70.2%; adjOR, 0.89 [0.67 – 1.19]) and BUD/FF groups (68.5% vs 69.4%; adjOR, 0.79 [0.58 – 1.08]). Non-inferiority of BDP/FF in preventing COPD exacerbation was fulfilled in both comparisons.
In patients without asthma, BDP/FF was also non-inferior to BUD/FF (proportion with COPD exacerbation: 67.8% vs 64.7%; adjOR, 0.79 [0.51 – 1.1997]). Additionally, significantly lower proportion of patients prescribed BDP/FF had COPD exacerbation compared to FP/SAL (64.8% vs 73.7%, adjOR, 0.64 [0.43 – 0.96]).
Initiating ICS/LABA treatment of COPD with extrafine formulation BDP/FF was non-inferior in preventing moderate/severe exacerbations compared to FP/SAL and BUD/FF.
|Number of pages||11|
|Journal||International journal of chronic obstructive pulmonary disease|
|Publication status||Published - 26 Nov 2020|
- Metered Dose Inhaler
- Dry Powder Inhaler
- Chronic Obstructive Pulmonary Disease
- Treatment efficacy
- Cost effectiveness
- Chronic obstructive pulmonary disease
- Dry-powder inhaler
- Metered-dose inhaler
- metered-dose inhaler
- dry-powder inhaler
- chronic obstructive pulmonary disease
- treatment efficacy